Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kobayashi Pharmaceutical CoKBYPF -2.71%79 EV-to-EBITDA is 26.78 as of Aug. 15, 2026, which is 26% above its 10-year median of 21.33. GuruFocus rates KBYPF with a GF Score™ of 79/100 and a GF Value™ of $26.62. The stock has 6 warning signs investors should review. Among 1,644 Consumer Packaged Goods companies, Kobayashi Pharmaceutical Co ranks worse than 87.04% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Kobayashi Pharmaceutical Co's enterprise value is $2,243 Mil.
Kobayashi Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $84 Mil. Therefore, Kobayashi Pharmaceutical Co's EV-to-EBITDA for today is 26.78.
The historical rank and industry rank for Kobayashi Pharmaceutical Co's EV-to-EBITDA or its related term are showing as below:
KBYPF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 10.63 Med: 21.33 Max: 63.48
Current: 28.85
During the past 13 years, the highest EV-to-EBITDA of Kobayashi Pharmaceutical Co was 63.48. The lowest was 10.63. And the median was 21.33.
KBYPF's EV-to-EBITDA is ranked worse than 87.04% of 1644
companies
in the Consumer Packaged Goods industry
Industry Median: 9.115
vs KBYPF: 28.85
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Kobayashi Pharmaceutical Co (OTCPK:KBYPF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kobayashi Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Kobayashi Pharmaceutical Co's share price for today is $34.05.
Kobayashi Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.291.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Household & Personal Products subindustry, Kobayashi Pharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kobayashi Pharmaceutical Co EV-to-EBITDA vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Kobayashi Pharmaceutical Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Kobayashi Pharmaceutical Co's EV-to-EBITDA falls into.
Kobayashi Pharmaceutical Co's current Enterprise Value is $2,243 Mil.
Kobayashi Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $84 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kobayashi Pharmaceutical Co (KBYPF) has a EV-to-EBITDA of 26.78 as of Aug. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Kobayashi Pharmaceutical Co. This is 26% above median its historical median of 21.33. Over the past decade, Kobayashi Pharmaceutical Co's EV-to-EBITDA has ranged from 10.63 to 63.48. According to the industry distribution chart, Kobayashi Pharmaceutical Co ranks #1431 out of 1644 companies in the Consumer Packaged Goods industry, placing it in the top 87%.
Is Kobayashi Pharmaceutical Co's EV-to-EBITDA too high?
Kobayashi Pharmaceutical Co's current EV-to-EBITDA of 26.78 is 26% above median its 10-year median of 21.33. Over the past 10 years, this metric has ranged from a low of 10.63 to a high of 63.48. The Consumer Packaged Goods industry median EV-to-EBITDA is 9.12. Kobayashi Pharmaceutical Co's value of 26.78 is 193.8% above this industry median. Based on the distribution chart, Kobayashi Pharmaceutical Co ranks #1431 out of 1644 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Kobayashi Pharmaceutical Co has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Kobayashi Pharmaceutical Co's EV-to-EBITDA compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Kobayashi Pharmaceutical Co ranks #1431 out of 1644 companies for EV-to-EBITDA. This places Kobayashi Pharmaceutical Co in the lower half of its industry. The industry median EV-to-EBITDA is 9.12. Kobayashi Pharmaceutical Co's value of 26.78 is 193.8% above this benchmark. Historically, Kobayashi Pharmaceutical Co's own EV-to-EBITDA has ranged from 10.63 to 63.48 over the past decade. While the company's 10-year median is 21.33 vs. the industry median of 9.12, Kobayashi Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Consumer Packaged Goods company?
The median EV-to-EBITDA among Consumer Packaged Goods companies is 9.12, based on 1,644 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kobayashi Pharmaceutical Co's current EV-to-EBITDA of 26.78 is 193.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Kobayashi Pharmaceutical Co. For the Consumer Packaged Goods industry, the median EV-to-EBITDA is 9.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kobayashi Pharmaceutical Co's current EV-to-EBITDA is 26.78, which is 26% above median its own 10-year median of 21.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kobayashi Pharmaceutical Co stock overvalued right now?
Kobayashi Pharmaceutical Co (KBYPF) has a current EV-to-EBITDA of 26.78. The stock's GF Value™ is $26.62, compared to a current price of $34.05 — trading 27.9% above its estimated fair value. The current EV-to-EBITDA is 26.78, which is 26% above median its 10-year median of 21.33 and 193.8% above the Consumer Packaged Goods industry median of 9.12. Kobayashi Pharmaceutical Co's overall GF Score™ is 79/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Kobayashi Pharmaceutical Co (KBYPF), the current EV-to-EBITDA is 26.78 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kobayashi Pharmaceutical Co (KBYPF) Overvalued in 2026?
Based on GuruFocus' analysis, Kobayashi Pharmaceutical Co stock appears to be overvalued.
The current stock price of $34.05 is trading 27.9% above its estimated GF Value™ of $26.62.
Key valuation signals for KBYPF:
EV-to-EBITDA: 26.78 (26% above median its 10-year median of 21.33)
GF Value™: $26.62 vs. price of $34.05 (27.9% above fair value)
Industry Position: 193.8% above the Consumer Packaged Goods median (#1431 of 1644)
No single metric tells the full story. See the KBYPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kobayashi Pharmaceutical Co Ltd is engaged in the manufacture and sale of healthcare products, daily necessities, and body warmers. The company operates through two reportable segments: Domestic Business and International Business, which handle production and sales activities in Japan and overseas, respectively. The company's product portfolio includes disposable body warmers, cooling gel sheets, OTC pharmaceuticals, oral hygiene products, air fresheners, eyeglass wipes, and deodorizing/household sundries.
79GF Score
Get the complete analysis for KBYPF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KBYPF has been successfully added to your 
